| препарат, замедляющий развитие раковой опухоли | marimastat (Marimastat was a proposed matrix metalloproteinase inhibitor developed by British Biotech. British Biotech was a British based biotech company. British Biotechnology Limited was founded in 1986 by former G D Searle managers Keith McCullagh and Brian Richards, [1] and was the first British biotechnology company to be publicly listed when it was floated on 1 July 1992 [2] In 1996, despite having no compounds on or near the market, it was temporarily valued at nearly $2.5 billion [3], largely on the basis of its two main development drugs, marimastat (a novel matrix metalloprotease inhibitor for cancer treatment [4]) and zacutex (for pancreatitis).Subsequent investigations by the Securities and Exchange Commission, Food and Drug Administration, London Stock Exchange and the European Medicines Evaluation Agency found that British Biotech had willfully misled the public about the progress of marimastat [6] and that unblinding data before the end of clinical trials does not necessarily invalidate the results.[7] Marimastat underwent Phase III trials in collaboration with Schering-Plough Corporation.; matrix metalloproteinase inhibitor Maria528) |
